CYR61 down-modulation induced by zoledronic acid impairs cell motility and sensitizes prostate cancer cells to docetaxel: A new anti-cancer strategy

Bone ◽  
2008 ◽  
Vol 42 ◽  
pp. S93
Author(s):  
M. Caraglia ◽  
M. Marra ◽  
G. Meo ◽  
S.R. Addeo ◽  
B. Vincenzi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Cell Motility ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Anti Cancer

scholarly journals CYR61 down-modulation sensitizes prostate cancer cells to zoledronic acid and docetaxel: A new anti-cancer strategy

2008 ◽  
Vol 6 (14) ◽  
pp. 123-124
Author(s):  
M. Caraglia ◽  
M. Marra ◽  
G. Meo ◽  
S. Zappavigna ◽  
B. Vincenzi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Anti Cancer

scholarly journals Preparation of Catechin Nanoemulsion from Oolong Tea Leaf Waste and Its Inhibition of Prostate Cancer Cells DU-145 and Tumors in Mice

Molecules ◽  
2021 ◽  
Vol 26 (11) ◽  
pp. 3260
Author(s):  
Yu-Hsiang Lin ◽  
Chi-Chung Wang ◽  
Ying-Hung Lin ◽  
Bing-Huei Chen
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Tumor Volume ◽  
Tween 80 ◽  
Prostate Cancer Cells ◽  
Caspase 9 ◽  
Oolong Tea ◽  
Induced Tumors ◽  
Anti Cancer ◽  
Tea Leaf

Anti-cancer activity of catechin nanoemulsions prepared from Oolong tea leaf waste was studied on prostate cancer cells DU-145 and DU-145-induced tumors in mice. Catechin nanoemulsions composed of lecithin, Tween-80 and water in an appropriate proportion was prepared with high stability, particle size of 11.3 nm, zeta potential of −67.2 mV and encapsulation efficiency of 83.4%. Catechin nanoemulsions were more effective than extracts in inhibiting DU-145 cell growth, with the IC50 being 13.52 and 214.6 μg/mL, respectively, after 48 h incubation. Furthermore, both catechin nanoemulsions and extracts could raise caspase-8, caspase-9 and caspase-3 activities for DU-145 cell apoptosis, arresting the cell cycle at S and G2/M phases. Compared to control, catechin nanoemulsion at 20 μg/mL and paclitaxel at 10 μg/mL were the most effective in reducing tumor volume by 41.3% and 52.5% and tumor weight by 77.5% and 90.6% in mice, respectively, through a decrease in EGF and VEGF levels in serum.

scholarly journals Combined Anti-Cancer Effects of Platycodin D and Sorafenib on Androgen-Independent and PTEN-Deficient Prostate Cancer

2021 ◽  
Vol 11 ◽  
Author(s):  
Zongliang Lu ◽  
Wei Song ◽  
Yaowen Zhang ◽  
Changpeng Wu ◽  
Mingxing Zhu ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Castration Resistance ◽  
Prostate Cancer Cells ◽  
Antitumor Effects ◽  
Platycodin D ◽  
Downstream Target ◽  
Anti Cancer ◽  
Pc3 Cells ◽  
Androgen Independent

Castration-resistant (androgen-independent) and PTEN-deficient prostate cancer is a challenge in clinical practice. Sorafenib has been recommended for the treatment of this type of cancer, but is associated with several adverse effects. Platycodin D (PD) is a triterpene saponin with demonstrated anti-cancer effects and a good safety profile. Previous studies have indicated that PC3 cells (PTEN -/-, AR -/-) are sensitive to PD, suggesting that it may also be a useful treatment for castration-resistance prostate cancer. We herein investigated the effects of combining PD with sorafenib to treat PTEN-deficient prostate cancer cells. Our data show that PD promotes sorafenib-induced apoptosis and cell cycle arrest in PC3 cells. Of interest, PD only promoted the anti-cancer effects of sorafenib in Akt-positive and PTEN-negative prostate cancer cells. Mechanistic studies revealed that PD promoted p-Akt ubiquitination by increasing the p-Akt level. PD also increased the protein and mRNA expression of FOXO3a, the downstream target of Akt. Meanwhile, PD promoted the activity of FOXO3a and increased the protein expression of Fasl, Bim and TRAIL. Interestingly, when FOXO3a expression was inhibited, the antitumor effects of both PD and sorafenib were individually inhibited, and the more potent effects of the combination treatment were inhibited. Thus, the combination of PD and sorafenib may exert potent anti-cancer effects specifically via FOXO3a. The use of Akt inhibitors or FOXO3a agonists, such as PD, may represent a promising approach for the treatment of androgen-independent and PTEN-deficient prostate cancer.

scholarly journals Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype

Oncotarget ◽  
2014 ◽  
Vol 6 (7) ◽  
pp. 5324-5341 ◽  
Author(s):  
Maria Rita Milone ◽  
Biagio Pucci ◽  
Katia Bifulco ◽  
Federica Iannelli ◽  
Rita Lombardi ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Zoledronic Acid ◽  
Cancer Cells ◽  
Proteomic Analysis ◽  
Prostate Cancer Cells ◽  
Invasive Phenotype

scholarly journals CRMP4a suppresses cell motility by sequestering RhoA activity in prostate cancer cells

2018 ◽  
Vol 19 (12) ◽  
pp. 1193-1203 ◽  
Author(s):  
Changlin Li ◽  
Haixia Xu ◽  
Lin Xiao ◽  
Haizhou Zhu ◽  
Guoan Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Motility ◽  
Cancer Cells ◽  
Prostate Cancer Cells ◽  
Rhoa Activity

Androgen-Responsive Lncap and Androgen-Independent Du145 Prostate Cancer Cells Display Different Taxol Sensitivities

1999 ◽  
Vol 5 (S2) ◽  
pp. 1110-1111
Author(s):  
Maureen Ripple ◽  
Meghan Taylo ◽  
Chris Huese ◽  
Heide Schatte
Keyword(s):  
Prostate Cancer ◽  
Cytochrome C ◽  
Cancer Cells ◽  
Metastatic Breast ◽  
Prostate Cancer Cells ◽  
Obvious Effect ◽  
C Elegans ◽  
Transfer Protein ◽  
Electron Transfer Protein ◽  
Anti Cancer

Taxol has been used as anti-cancer compound against prostate, ovarian, and metastatic breast cancer. While the most obvious effect of taxol is bundeling of microtubules and mitotic arrest, recent studies have demonstrated that taxol is able to induce intranucleosomal DNA fragmentation and typical morphological features of apoptosis in a number of solid tumor cells. These results indicate that taxol may exert its anti-tumor effects via secondary mechanisms which may or may not be related to its primary effects on microtubules. It has been shown that taxol-induced microtubular changes and G2/M arrest are associated with the release of the electron transfer protein cytochrome C from mitochondria into the cytosol. Cytochrome C then binds to APAF-1 (a human homolog of the ced-4 gene of C. elegans), which binds, cleaves, and activates caspase- 9, ultimately resulting in the cleavage and activity of caspase-3. We investigated the effects of taxol (100nM) on microtubules, on DNA, and on the pre-apoptotic mitochondrial events using LNCaP and DU145 prostate cancer cells.

Novel titanocene anti-cancer drugs and their effect on apoptosis and the apoptotic pathway in prostate cancer cells

APOPTOSIS ◽  
2006 ◽  
Vol 11 (7) ◽  
pp. 1205-1214 ◽  
Author(s):  
K. O'Connor ◽  
C. Gill ◽  
M. Tacke ◽  
F.-J. K. Rehmann ◽  
K. Strohfeldt ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Cells ◽  
Cancer Drugs ◽  
Prostate Cancer Cells ◽  
Apoptotic Pathway ◽  
Anti Cancer
Sign in / Sign up

Export Citation Format

Share Document